REG - BioVentix PLC - Exercise of Options and Issue of Equity

BioventixAnnouncement

11/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250411:nRSK6222Ea&default-theme=true

RNS Number : 6222E  BioVentix PLC  11 April 2025

Bioventix plc

("Bioventix" or the "Company")

Option Exercise, Director/PDMR Shareholding, and Total Voting Rights

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, was notified on 10 April 2025 that 5,204 options were
exercised over its ordinary shares of 5 pence each ("Ordinary Shares") by
Peter Harrison, Chief Executive Officer, at a price of 1,350 pence per
Ordinary Share.

Following this transaction, Mr Harrison's holding in the Company is as
detailed below:

 Director        Number of options exercised  Number of options held post exercise  Number of Ordinary Shares post-exercise held  Resulting interest in fully diluted share capital %

 Peter Harrison  5,204                        19,811                                302,292                                       5.79%

 

Application will be made for 5,204 new Ordinary Shares to be admitted to
trading on AIM. Admission is expected to become effective on 16 April 2025.
Following Admission, the Company will have 5,224,860 Ordinary Shares in issue.
All Ordinary Shares shall have equal voting rights and none of the Ordinary
Shares are held in treasury. The total number of voting rights in the Company
immediately following Admission will therefore be 5,224,860.

 

For further information please contact:

 Bioventix plc                                               Tel: 01252 728 001
 Peter Harrison                     Chief Executive Officer
 Bruce Hiscock                      Chief Financial Officer

 Cavendish Capital Markets Limited                           Tel: 020 7220 0500
 Geoff Nash / Elysia Bough          Corporate Finance
 Nigel Birks / Harriet Ward         ECM

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name of PDMR                                                 Peter Harrison
 2   Reason for notification

 a.  Position/Status                                              Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Bioventix plc
 b.  LEI                                                          213800225MHX7LZQY108
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary Shares of 5 pence each

     Identification Code

                                                                  GB00B4QVDF07

 b.  Nature of the transaction                                    Exercise of Options over Ordinary Shares
 c.  Price(s) and volume(s)                                                        No. of Shares  Price

                                                            Option exercise  5,204          1,350p

 d.  Aggregated information

     - Aggregated Volume                                          See above

     - Price
 e.  Date of the transaction                                      10 April 2025

 f.  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

See above

e.

Date of the transaction

10 April 2025

 

f.

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPKDBPDBKKQQD